AstraZeneca to Expand Presence in China - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

AstraZeneca to Expand Presence in China

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca entered into an agreement to acquire Guangdong BeiKang Pharmaceutical, a privately owned generic-drug manufacturing company based in Guangdong province, China, for an undisclosed amount. Guangdong BeiKang Pharmaceutical’s portfolio includes injectable medicines used to treat infections. Upon completion of the acquisition, AstraZeneca will be responsible for the manufacture and commercialization of these medicines. The deal is contingent upon approval from the Ministry of Commerce in China and is expected to close in the first quarter of 2012.

AstraZeneca first established a presence in China in 1993 and has invested around $500 million in China since that time, according to a company press release. In October 2011, AstraZeneca invested $200 million in a new manufacturing facility located in the Jiangsu province that will produce intravenous and oral solid medicines for the company’s growing business in China. The acquisition of Guangdong BeiKang Pharmacuetical accelerates AstraZeneca’s strategy, which aims to increase the accessibility and affordability of medicines for wider patient populations that are currently underserved.

“AstraZeneca continues to invest in the key emerging markets such as China where the combination of growing populations, elevated levels of chronic diseases, and increasing income are driving demand and expectations for better healthcare treatment,” said Mark Mallon, president of AstraZeneca’s Asia-Pacific region, in the press release. “Our new acquisition further underscores our intention to serve the health needs of Chinese patients through our innovative medicines and, increasingly, high-quality branded generic treatments that are locally produced to global standards.”

See related Pharm Tech article:

AstraZeneca Plans $200-Million Manufacturing Plant in China (ePT)


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here